Preparation, characterization and in vitro evaluation of solid dispersions containing docetaxel

Drug Development and Industrial Pharmacy

Volumn 34, Issue 6, 2008, Pages 588-594

  Chen, Jie ^a,b   Qiu, Liyan ^a   Hu, Minxin ^a   Jin, Yi ^a   Han, Jieru ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b Zhejiang XianJu Pharmaceutical Technology Co LTD   (China)

Author keywords

Crystallinity; Dissolution; Docetaxel; Poloxamer 188; Solid dispersion; Solubility

Indexed keywords

ACETONE; ALCOHOL; DOCETAXEL; DRUG CARRIER; DRUG SOLVENT; POLOXAMER;

ARTICLE; DIFFERENTIAL SCANNING CALORIMETRY; DISPERSION; DRUG FORMULATION; DRUG SCREENING; DRUG SOLUBILITY; DRUG SYNTHESIS; ENVIRONMENTAL SCANNING ELECTRON MICROSCOPE; IN VITRO STUDY; MOLECULAR INTERACTION; SCANNING ELECTRON MICROSCOPE; X RAY DIFFRACTION;

ANTINEOPLASTIC AGENTS; BIOLOGICAL AVAILABILITY; CALORIMETRY, DIFFERENTIAL SCANNING; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG CARRIERS; DRUG STABILITY; EXCIPIENTS; GLYCERIDES; MICROSCOPY, ELECTRON, SCANNING; POLOXAMER; POVIDONE; SOLUBILITY; TAXOIDS; X-RAY DIFFRACTION;

EID: 45849092587     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.1080/03639040701831835     Document Type: Article

References (23)

1. Albert, J., Ten, T., Verweij, J., Loos, W. J., & Sparreboom, A. (2003). Pharmacological effects of formulation vehicles: Implications for cancer chemotherapy. Clin. Pharmacokinet, 42, 665-685.
2. Bardelmeijer, H. A., Ouwehand, M., Buckle, T., Huisman, M. T., Schellens, J. H. M., Beijnen, J. H., & Tellingen, O. V. (2002). Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavir. Cancer Res., 62, 6158-6164.
3. Bissery, M. C. (1995). Preclinical pharmacoligy of docetaxel. Eur. J. Cancer., 31, s1-s6.
4. Chutimaworapan, S., Ritthidej, G. C., Yonemochi, E., Oguchi, T., & Yamamoto, K. (2000). Effect of water-soluble carriers on dissolution characteristics of nifedipine solid dispersions. Drug Dev. Ind. Pharm., 26, 1141-1150.
5. Clarke, S. J., & Rivory, L. P. (1999). Clinical pharmacokinetics of docetaxel. Clin. Pharmacokinet., 36, 99-114.
6. Franco, M., & Trapani, G. (2001). Dissolution properties and anticonvulsant activity of phenytoin-polyethylene glycol 6000 and polyvinylpyrrolidone K-30 solid dispersions. Int. J. Pharm., 225, 63-73.
7. Franco, Y., & Zhang, G. G. Z. (2004). Enhancing the bioavailability of ABT-963 using solid dispersion containing Pluronic F-68. Int. J. Pharm., 286, 69-80.
8. Jannin, V., Pochard, E., & Chambin, O. (2006). Influence of poloxamers on the dissolution performance and stability of controlled-release formulations containing Precirol® ATO 5. Int. J. Pharm., 309, 6-15.
9. Kim, E. J., Chun, M. K., Jang. J. S., Lee, I. H., Lee, K. R., & Choi, H. K. (2006). Preparation of a solid dispersion of felodipine using a solvent wetting method. Eur. J. Pharm. Biopharm., 64, 200-205.
10. Leuner, C., & Dressman, J. (2000). Improving drug solubility for oral delivery using solid dispersions. Eur. J. Pharm. Biopharm., 50, 47-60.
11. Maria, L. I., Paola, B., Silvia, A., Barbra, S., Franco, D., & Luigi, C. (2003). Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing docetaxel. J. Controlled Release, 91, 417-429.
12. Markman, M. (2003). Managing taxane toxicities. Support Care Cancer, 11, 144-147.
13. Musumeci, T., Ventura, C. A., Giannone, I., Montenegro, L., Ruozi., B., Pignatello, R., & Puglisi, G. (2006). PLA/PLGA nanoparticles for sustained release of docetaxel. Int. J. Pharm., 325, 172-179.
14. Nannan, P. R., & Huizing, M. T. (1997). Hypersensitivity reactions to the taxanes paclitaxel and docetaxel. Clin. Drug Investing, 14, 418-427.
15. Nuijen, B., Bouma, M., Schellens, J. H. M., & Beijnen, J. H. (2001). Progress in the development of alternative pharmaceutical formulations of taxanes. Invest. New Drug, 19, 143-153.
16. Ringel, I., & Horwitz, S. B. (1991). Studies with RP56976 (taxotere): A semisynthetic analogue of taxol. J. Natl. Cancer Inst., 83, 288-291.
17. Rowe, R. C., Sheskey, P. J., & Weller, P. J. (2003). Handbook of pharmaceutical excipients (4th ed.). Washington, DC: Pharmaceutical Press and American Pharmaceutical Association.
18. Sanofi aventis website. (no date). For U.S. residents only. Retrieved January 20, 2007, from: http://en.sanofi-aventis.com/index.asp.
19. Sheen, P. C., Khetarpal, V. K., Cariola, C. M., & Rowlings, C. E. (1995). Formulation studies of a poorly water-soluble drug in solid dispersions to improve bioavailability. Int. J. Pharm., 118, 221-227.
20. Shin, S. H., Jin, K. (2003). Physicochemical characterization of solid dispersion of furosemide with TPGS. Int. J. Pharm., 251, 79-84.
21. Takigawa, N., & Segawa, Y. (2004). Clinical and pharmacokinetic study of docetaxel in elderly non-small-cell lung cancer patients. Cancer Chemother Pharmacol., 54, 230-236.
22. Tham, Y. L., & Gomez, L. F. (2005) Clinical response to neoadjuvard docetaxel predicts improved outcome in patients with large locally advanced breast cancers. Breast Cancer Res. Tr., 94, 279-284.
23. Verheyen, S., Blaton, N., Kinget, R., & Mooter, G. V. D. (2002). Mechanism of increased dissolution of diazepam and temazepam from polyethylene glycol 6000 solid dispersions. Int. J. Pharm., 249, 45-58.